Related topics: Industry Drivers
Wyeth is cutting back on its early stage R&D efforts to focus on oncology, inflammation, vaccines, metabolic diseases, musculoskeletal problems and neuroscience.
The move, which is part of the firm’s Project Impact restructuring strategy is in keeping with refocusing efforts made by rivals such as Pfizer, Eli Lilly and Bristol-Myers Squibb in recent months.
Wyeth spokesman Michael Lampe told Reuters that the plans were not a cost-reduction exercise and would affect neither its level of R&D spending or personnel.
Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
